Breast cancer therapies get nod

Breast cancer is making headlines today: Eli Lilly got the FDA's nod to market its osteoporosis drug Evista as a breast cancer preventative, and Genentech got word that the agency will consider its colon-and-lung cancer drug Avastin for breast cancer treatment.

Evista, classified as an estrogen agonist/antagonist, now can be sold specifically to prevent breast cancer in postmenopausal osteoporosis patients and in postmenopausal patients at high risk of invasive tumors. The risk of both osteoporosis and breast cancer increases dramatically after menopause. Avastin's usefulness against breast cancer will be debated at an FDA advisory committee meeting December 4-5. The drug already is used off-label against the disease; its second quarter sales amounted to $564 million.

- see Eli Lilly's release
- read the Indianapolis Star report
-
the AP has this report on Avastin

Related Articles:
Lilly's Evista fails to prevent heart attacks. Report
Study points to serious risks from Evista. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.